To animate the Banner
Talent Recruitment
Apply for post
Recruitment Position
Place of work
Number of Recruits
Salary Treatment
Tancituzumab
Tancituzumab (Tafasitamab), a humanized monoclonal antibody targeting CD19, mediates lysis of B- cell tumors through apoptotic and immune effector mechanisms. The tanxituzumab treatment scheme has been approved for listing in Hong Kong, approved for use in Boao and included in the "Hong Kong and Macao Drug Association" in Dawan District. The registered clinical trial of tanxituzumab combined with lenalidomide for the treatment of relapsed/refractory diffuse large B cell lymphoma (DLBCL) has been completed in China, and BLA listing application is expected to be submitted in 2024. From first-line to second-line and above DLBCL treatment, Nuocheng Jianhua depth layout, the development of a variety of drug combinations, for this aggressive lymphoma to provide more and better treatment options. Five-year follow-up data showed that tandituzumab in combination with lenalidomide, followed by tandituzumab monotherapy, provided long-term and durable remission in adults with relapsed/refractory DLBCL, with an optimal overall response rate (ORR) of 57.5 percent (primary endpoint). DLBCL is the most common form of non-Hodgkin lymphoma (NHL), accounting for 31% to 34% of NHL cases worldwide. In China, DLBCL accounts for 45.8 percent of all NHLs. Tancintuzumab combined with lenalidomide for the treatment of relapsed/refractory DLBCL has been recommend by the Chinese CSCO clinical diagnosis and treatment guidelines.
Focus on us
Contact Information
Monday to Friday 9:00~17:00
Rooms 801-808 and 901-908, Building H, No. 3 Jiu Quan Road, Huangpu District, Guangzhou City
Copyright©2024 Virotech Pharmaceutical Technology Co., Ltd.
